Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition.

Frontiers in Oncology
Jingyu PengWei Wei

Abstract

Cyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and gene expression transcriptional regulation, which are often not assessed in cancer developing process. CDK7 inhibitors have emerged as promising drugs for treating diverse cancers, including breast cancer. However, the mechanism behind its anticancer effect has not been well investigated. Here, the possible mechanism of CDK7 inhibitors for treating human triple-negative breast cancer (TNBC) has been studied. The effects of CDK7 inhibitors on breast cancer cells have been identified by measuring cell viability (Cell Counting Kit-8) and cell proliferation and calculating colony formation. The short hairpin RNA and short interfering RNA were used for the construction of knockdown cells. To assess the expression of associated proteins, western blot was used. This study confirmed that, compared to hormone receptor-positive breast cancer cells, TNBC cells were more sensitive to THZ1, a novel CDK7 inhibitor. THZ1 treatment specifically downregulated mutated p53 in a dose- and time-dependent manner in TNBC cells with p53 mutation. Another CDK7 inhibitor, LDC4297, also potently interfered with the expression of mutated p53. Furthermore, endogenous CDK7 expression...Continue Reading

References

Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
May 8, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laxmi Silwal-PanditAnita Langerød
Jul 22, 2014·Nature·Nicholas KwiatkowskiNathanael S Gray
Sep 3, 2014·Genome Biology·Marcos Malumbres
May 3, 2016·Nature·Serena Nik-ZainalMichael R Stratton
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Nov 4, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hetal PatelSimak Ali
Sep 13, 2016·International Journal of Cancer. Journal International Du Cancer·N C SynnottM J Duffy
May 16, 2017·Oncogenesis·S A GreenallT G Johns
May 8, 2018·The Journal of Pharmacology and Experimental Therapeutics·Wei WangZhao-Hui Wu
Jan 23, 2019·JAMA : the Journal of the American Medical Association·Adrienne G Waks, Eric P Winer
Mar 25, 2019·Cell Chemical Biology·Calla M OlsonNathanael S Gray
Mar 10, 2020·Journal of Medicinal Chemistry·Sarah DiabShudong Wang
May 10, 2020·Cancer Metastasis Reviews·Georgina P SavaSimak Ali

❮ Previous
Next ❯

Software Mentioned

ArcSoft
GraphPad Prism
ImageJ
- Stitch Deluxe
OLYMPUS cellSens Standard
Scan

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.